O-17 Thalidomide analogue CC5013 (revlimid) selectively...

Leukemia Research 2005 Vol. 29; Iss. supp-S1

O-17 Thalidomide analogue CC5013 (revlimid) selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5Q deletion

M. Jadersten, A.-M. Forsblom, E.K. Emanuelsson, M. Merup, E. Hellström-Lindberg
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
29
Year:
2005
Language:
english
Pages:
1
DOI:
10.1016/s0145-2126(05)80016-5
File:
PDF, 80 KB
english, 2005
Conversion to is in progress
Conversion to is failed